GeoVax Labs, Inc. has received positive guidance from the EMA for their GEO-MVA vaccine, allowing for a single Phase 3 trial to evaluate efficacy against Mpox and smallpox. This streamlined process could accelerate regulatory approval, providing a critical new vaccine source amidst the Mpox emergency.
